Effect of blonanserin on cognitive impairment in schizophrenic patient-non-blinded, randomized, comparative study with olanzapine

Effect of blonanserin on cognitive impairment in schizophrenic patient-non-blinded, randomized, comparative study with olanzapine - Effect of blonanserin on cognitive impairment in schizophrenic patient

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008217

Enrollment

Registered

2012-08-01

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

antipsychotics(blonanserin) antipsychotics(olanzapine)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Schizophrenic patient(ICD-10,DSM-4-TR) PANSS total score over 61 points Clinical Global Impressions(CGI) over 4 points Regardless of the sex, age and inpatient or outpatient

Exclusion criteria

Exclusion criteria: blonanserin or olanzapine administration (within 1 month before trial) clozapine prescription (within 3 month before trial) coma seizure disorders,brain organic disease serious complication drug,alcohol abuse diabetes mellitus pregnancy,possibility of pregnancy dementia

Design outcomes

Primary

Measure	Time frame
BACS-J	—

Countries

Japan

Contacts

Public ContactToru Sasada

Faculty of Medical Science, Kobe University Graduate School of Medicine Department of Psychiatry

078-382-6065

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026